À̹ÌÁö È®´ë [Photo provided by Chong Kun Dang]
South Korea¡¯s Ministry of Food and Drug Safety said on Monday it has started regulatory review of Chong Kun Dang (CKD)¡¯s pancreatitis drug Napabeltan (nafamostat mesylate) 50§· to add a potential indication for the treatment of coronavirus symptoms.
If approved, Napabeltan will become the country¡¯s second Covid-19 cure following Rekirona (regdanvimab), Celltrion¡¯s neutralizing antibody therapy, which was approved last month.
Last year, CKD filed for emergency use authorization of Napabeltan with the ministry in parallel with approval for its Phase 3 trial after completing a Phase 2 study of Napabeltan in 104 high-risk patients with severe symptoms in Russia.
In the Phase 2 study, 61.1 percent of patients treated with Napabeltan for 10 days achieved recovery, demonstrating superiority to the standard therapy arm where only 11.1 percent achieved recovery.
After a designed follow-up period of 28 days, 94.4 percent of patients in the Napabeltan group achieved recovery versus 61.1 percent in the comparator group.
Safety-wise, four deaths were reported in the standard therapy group but there was no death in the Napabeltan group.
CKD¡¯s Phase 3 study aims to evaluate the drug in some 600 high-risk patients with severe symptoms at more than 10 centers across Korea, including Seoul National University Hospital. A global clinical trial will be conducted to ensure fast patient enrollment.
The company expects the drug¡¯s unique mechanism of action to respond to even mutants of Covid-19 that are evolving globally. Napabeltan would be the only proven treatment option in the treatment of high-risk patients with severe symptoms if it is approved. Rekirona was approved for the treatment of high-risk patients with mild to moderate symptoms.
The ministry is applying a fast-track review program to coronavirus cures and vaccines, cutting the timeframe from six months to less than 40 days.
By Pulse
[¨Ï Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]